TT-012, MITF dimer disruptor

Potent and selective MITF dimerization disruptor with significant efficacy against melanoma both in vitro and in vivo.
TT-012 is a highly effective microphthalmia-associated transcription factor (MITF) dimerization inhibitor (Kd = 15.5 nM for the bHLH-LZ domain) that specifically targets melanoma by disrupting MITF′s DNA-binding activity. TT012 exhibits notable potency in inhibiting MITF dimer formation (IC50 = 13.1 nM) and reducing the growth of B16F10 melanoma cells (IC50 = 499 nM), while also lowering mRNA levels of MITF target genes in these cells (IC50 < 3.12 µM). TT 012 is particularly effective against melanoma cells with elevated MITF expression and markedly diminishes tumor growth and pulmonary metastasis in mice, achieving reductions of 79.7% and 93.9% at dosages of 2 mg/kg and 5 mg/kg, respectively, compared to controls.